Mechanisms of CLBP and MDD Comorbidity: Implications for Precision Medicine

Understanding the Comorbidity of CLBP and MDD

Chronic low back pain (CLBP) and major depressive disorder (MDD) frequently occur together, presenting a significant challenge in clinical settings. A recent review published on OpenAlex highlights the intricate interplay of neural, immune, endocrine, and gut-brain axis interactions that underpin this comorbidity. The study synthesizes findings from 86 studies conducted between 2015 and 2025, providing a comprehensive overview of the pathophysiological mechanisms involved.

Mechanisms Driving Comorbidity

The pathogenesis of CLBP and MDD comorbidity is driven by dysregulation in the neural-immune-endocrine-gut-brain axis. Key mechanisms include the phosphorylation of spinal dorsal horn NMDA receptor NR2B, which amplifies pain signals, and the connectivity between the anterior cingulate cortex and insula, correlating with depression severity. Additionally, microglial TLR4/NF-κB activation significantly increases pro-inflammatory cytokines, while HPA axis dysfunction alters cortisol rhythms. Gut dysbiosis further complicates the condition by reducing short-chain fatty acids and increasing pro-inflammatory bacterial populations.

Implications for Precision Medicine

Understanding these mechanisms is crucial for developing precision medicine approaches. The review suggests that targeting specific neural circuits, addressing neuroinflammation, and modulating the gut-brain axis could enhance diagnostic accuracy and therapeutic efficacy. For instance, duloxetine and closed-loop spinal cord stimulation (SCS) have shown promise in clinical trials, reducing pain and depression scores significantly. Electroacupuncture also emerged as a potential treatment, alleviating symptoms in a majority of patients.

Risks and Unknowns in Current Approaches

While these findings are promising, they are primarily based on existing studies and require further validation in clinical settings. The long-term efficacy of treatments like duloxetine and SCS diminishes over time, possibly due to neural circuit re-remodeling and serotonin transporter upregulation. Additionally, electroacupuncture's benefits may be undermined by secondary gut microbiota dysbiosis. These challenges highlight the need for ongoing research and adaptation of treatment strategies.

Future Directions in Research and Policy

Future research should focus on validating these mechanisms in diverse patient populations and refining precision medicine strategies. Multidisciplinary collaboration will be essential to overcome diagnostic and therapeutic bottlenecks. Policymakers and healthcare providers must also consider integrating these insights into clinical practice, ensuring that treatment plans are tailored to the unique biological profiles of patients with CLBP and MDD comorbidity.